World Conference on Oncology & Cancer Care (WCOCC-2026)

  Myeloid-Derived Suppressor Cells in Cancer: New Frontiers in Cancer Immunotherapy Introduction Cancer progression is influenced not only by malignant cells but also by the complex biological environment surrounding them. Immune cells, stromal cells, blood vessels, signaling molecules, and metabolic factors interact within the tumor microenvironment (TME) and can shape tumor growth and treatment response. Among these components, myeloid-derived suppressor cells (MDSCs) have attracted increasing attention in cancer research. MDSCs are a heterogeneous group of myeloid cells that can accumulate during chronic inflammation and cancer and suppress important antitumor immune functions. They can interfere with T cells and natural killer (NK) cells and contribute to immune escape, tumor progression, metastasis, and resistance to some cancer treatments. The growing understanding of MDSC biology has opened new research directions in cancer immunology. Scientists are investigating h...

  Tertiary Lymphoid Structures in Cancer: New Frontiers in Tumor Immunity and Immunotherapy Introduction Cancer is not driven by tumor cells alone. The surrounding tumor microenvironment contains immune cells, blood vessels, stromal cells, signaling molecules, and extracellular structures that can strongly influence how a tumor grows and how it responds to treatment. Among the emerging areas of cancer immunology, tertiary lymphoid structures (TLS) have attracted increasing attention because of their potential role in organizing local immune responses against tumors. Tertiary lymphoid structures are organized collections of immune cells that develop in tissues outside conventional lymphoid organs such as lymph nodes and the spleen. Unlike normal secondary lymphoid organs, TLS are generally formed in response to chronic inflammation, infection, autoimmune processes, or cancer. Within tumors, these structures can create specialized local environments where immune cells interact...

  Drug Repurposing in Oncology: New Strategies for Faster Cancer Treatment Development Cancer treatment continues to evolve as researchers search for safer, more effective, and more personalized therapeutic strategies. Although the development of new cancer medicines has produced major advances, discovering and bringing an entirely new drug to patients can require substantial time, investment, and extensive clinical evaluation. One emerging strategy that has attracted increasing interest in oncology is drug repurposing . Also known as drug repositioning, this approach involves investigating medicines that are already approved or previously developed for one disease to determine whether they may be useful for treating cancer or a different cancer indication. Rather than starting drug development from the beginning, researchers can leverage existing knowledge about a medicine's pharmacology, safety profile, mechanism of action, and manufacturing characteristics. This can potent...